Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors.
Curcumin (diferuloylmethane) is the main active ingredient of turmeric, a traditional herbal medicine and food of south Asia. Curcumin has been found to have a wide range of biological activities, including antioxidant, anti-inflammatory, chemopreventive and chemotherapeutic activities. Curcumin is currently being tested in clinical trials for treatment of various types of cancers, including multiple myeloma, pancreatic cancer and colon cancer. Although no toxicity associated with curcumin (even at very high doses) has been observed, the effects of curcumin in other solid tumors have been modest, primarily due to poor water solubility and poor bioavailability in tissues remote from the gastrointestinal tract. Therefore, there is a need for the discovery of curcumin analogs with better water solubility or greater bioavailability for the treatment of solid tumors such as prostate cancer. In this study, curcumin acetates and amino acid conjugates of curcumin were studied in terms of their proteasome inhibitory and antiproliferative effects against several human cancer cell lines. It was found that the water soluble amino acid conjugates of curcumin showed a potent antiproliferative effect and are potent proteasome inhibitors. Docking studies of the curcumin amino acid conjugates for proteasome inhibition were carried out to explain their biological activities. It is suggested that they may serve as the water soluble analogs of curcumin.
Wan
Sheng Biao
SB
Department of Applied Biology and Chemical Technology and the Open Laboratory for Chiral Technology, The Institute of Molecular Technology for Drug Discovery and Synthesis, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, P.R. China.
Yang
Huanjie
H
Zhou
Zhongyuan
Z
Cui
Qiuzhi Cindy
QC
Chen
Di
D
Kanwar
Jyoti
J
Mohammad
Imthiyaz
I
Dou
Q Ping
QP
Chan
Tak Hang
TH
D000085:Acetates / Q000737:chemistry / Q000494:pharmacology; D000596:Amino Acids / Q000737:chemistry / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D030024:Curcuma / Q000737:chemistry; D003474:Curcumin / Q000737:chemistry* / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry / Q000378:metabolism*; D061988:Proteasome Inhibitors; D011485:Protein Binding; D012995:Solubility
D000085:Acetates; D000596:Amino Acids; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D061988:Proteasome Inhibitors; D046988:Proteasome Endopeptidase Complex; D003474:Curcumin
Adv Exp Med Biol. 2007;595:1-75
17569205
Cell Death Differ. 1998 Dec;5(12):1062-75
9894613
Cell Mol Life Sci. 2008 Jun;65(11):1631-52
18324353
Bioorg Med Chem. 2004 Nov 1;12(21):5587-93
15465336
Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):105-11
11815407
Br J Cancer. 2004 Mar 8;90(5):1011-5
14997198
Planta Med. 1991 Feb;57(1):1-7
2062949
Eur J Med Chem. 2008 Sep;43(9):1837-46
18201805
Drug Resist Updat. 2006 Dec;9(6):263-73
17197231
Clin Cancer Res. 2007 Feb 15;13(4):1269-77
17317839
Drug Metab Dispos. 1999 Apr;27(4):486-94
10101144
Curr Protein Pept Sci. 2008 Jun;9(3):227-39
18537678
Genes Cells. 2006 Mar;11(3):223-35
16483311
Clin Cancer Res. 1999 Apr;5(4):891-7
10213226
Br J Haematol. 2004 Oct;127(2):165-72
15461622